Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TKPHF) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for Takeda Pharmaceutical (TKPHF) over the last 8 years, with Q4 2025 value amounting to $2.7 billion.

  • Takeda Pharmaceutical's Free Cash Flow fell 444.56% to $2.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.5 billion, marking a year-over-year decrease of 249.21%. This contributed to the annual value of $6.6 billion for FY2025, which is 2829.49% up from last year.
  • As of Q4 2025, Takeda Pharmaceutical's Free Cash Flow stood at $2.7 billion, which was down 444.56% from $2.8 billion recorded in Q3 2025.
  • Takeda Pharmaceutical's 5-year Free Cash Flow high stood at $3.9 billion for Q1 2021, and its period low was $129.6 million during Q1 2025.
  • For the 5-year period, Takeda Pharmaceutical's Free Cash Flow averaged around $2.0 billion, with its median value being $1.8 billion (2022).
  • Per our database at Business Quant, Takeda Pharmaceutical's Free Cash Flow skyrocketed by 70304.68% in 2021 and then crashed by 8898.09% in 2025.
  • Over the past 5 years, Takeda Pharmaceutical's Free Cash Flow (Quarter) stood at $3.3 billion in 2021, then decreased by 11.57% to $2.9 billion in 2022, then tumbled by 55.07% to $1.3 billion in 2023, then surged by 115.45% to $2.8 billion in 2024, then fell by 4.45% to $2.7 billion in 2025.
  • Its Free Cash Flow stands at $2.7 billion for Q4 2025, versus $2.8 billion for Q3 2025 and $1.8 billion for Q2 2025.